There are some risks...increased damage to your platelets, increased bleeding.

还是有一定的风险的...对的损害和出倾向。

In case of platelets, progenitor cells differentiate into megakaryocytes, which are responsible for creating platelets.

在的生成过程中，造细胞会分化成巨核细胞；由巨核细胞来制造。

It also makes the platelets that cause clotting to stop bleeding well.

同时，它还产生能够使液凝固，从而起到止作用的。

The idea of coating equipment with platelet membranes has been around for a while.

在设备上涂上膜的想法已经存在一段时间了。

These platelets then recruit additional platelets to form a platelet plug.

这些随即招募其他的来形成栓。

Platelets only last around four or five days, so supplies have to be constantly replenished with donations, resulting in wastage.

只能维持4到5天左右，所以必须不断地用捐献的补充供应，从而导致不的浪费。

Laboratory findings in disseminated intravascular coagulation include decreased platelets and decreased fibrinogen.

弥散性管内凝的实验室检查结果包括降低的和降低的纤维蛋白原。

Now, if the number of platelets is extremely high, over 1.5 million, then there's an increased risk of bleeding.

如果的量很高，超过了150万，出的风险就会增加。

This might be due to aspirin's anti-platelet effects.

这可能是由于阿司匹林的抗作用。

Ischemic heart disease caused by coronary artery atherosclerosis, or plaque buildup, is the most common cause.

由冠状动脉粥样硬化或积聚引起的缺性心脏病变是左心衰最常见的病因。

The primary risk factors for cardiovascular disease — obesity, diabetes, smoking and so on are linked to platelet activation and clotting.

肥胖、糖尿病、抽烟等，这些都与的活性和凝有关。

So if your platelets don’t work normally, it’s not as much of a problem.

因此，如果您的不能正常工作，那也不是什么大问题。

Normally, the liver and kidneys produce a tiny hormone called thrombopoietin which binds to hematopoietic cell receptors.

正常情况下，肝脏和肾脏会合成一种叫做促生成素的激素，可以与造细胞受体结合。

Treatment of essential thrombocythemia depends on risk of blood clots.

原发性增多症的治疗取决于栓形成的风险。

In individuals with extremely high platelet counts, plateletpheresis can be used.

对于计极高的患者，可以采用单采治疗。

It resembles a condition known as heparin-induced thrombotic thrombocytopenia, which occurs occasionally with the blood-thinner heparin.

它类似于一种被称为肝素诱导的栓性减症的病症，这种病症偶尔会与液稀释剂肝素一起发生。

The formation of the platelet plug is called primary hemostasis.

栓子的形成叫做一期止。

Cells can also develop mutations in the thrombopoietin receptor, MPL, or in the chaperone protein, Calreticulin or CalR.

细胞内的促生成素受体（MPL）或伴侣蛋白/钙网蛋白（CalR）也可以发生突变。

First my blood is treated to make a concentrated solution of platelets in plasma. Next, this is injected directly into my face.

首先通过对我液的处理获得富含的浆。然后这些浆被直接注入我的面部。

Then, some platelets adhere to the damaged vessel wall, and become activated and then recruit additional platelets to form a plug.

随后，粘附到受损处的管壁上并被激活，再募集更多的形成栓子。